Huaiwei Ding

DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis.

Qiong Wu, Xiangbo Xu, Xiaochun Qin, 2022, Biochemical pharmacology.

DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer

Yingshi Zhang, Chang Xu, Qiong Wu, 2022, Frontiers in Oncology.

S9, a Novel Anticancer Agent, Exerts Its Anti-Proliferative Activity by Interfering with Both PI3K-Akt-mTOR Signaling and Microtubule Cytoskeleton

Hualiang Jiang, Jian Ding, C. Luo, 2009, PloS one.

ZDQ-0620, a Novel Phosphatidylinositol 3-Kinase Inhibitor, Inhibits Colorectal Carcinoma Cell Proliferation and Suppresses Angiogenesis by Attenuating PI3K/AKT/mTOR Pathway

Chang Xu, Xiang-bo Xu, Xiaochun Qin, 2022, Frontiers in Oncology.

Integration of MyD88 inhibitor into mesoporous cerium oxide nanozymes-based targeted delivery platform for enhancing treatment of ulcerative colitis.

Xing Tang, Yu Zhang, Haibing He, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Abstract #3391: S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton

Hualiang Jiang, Jian Ding, C. Luo, 2009 .